Key result
Early use of β blockers reduced 30 day mortality to 2.3% compared to 8.6% in non-users, with an adjusted.46.
Why the study?
Does beta-blocker therapy reduce short-term and long-term mortality in patients with acute myocardial infarction without heart failure or left ventricular dysfunction?
Cohort (n=2,679)
Yes
Does beta-blocker therapy reduce short-term and long-term mortality in patients with acute myocardial infarction without heart failure or left ventricular dysfunction?
Early beta-blocker use post-myocardial infarction improves 30-day survival, but prolonged use beyond one year in patients without heart failure or left ventricular dysfunction does not confer a 5-year mortality benefit.
Answers are grounded in this paper and cite their sources.
Early β-blocker use was associated with lower 30-day mortality post-MI without HF; leaves open benefit of therapy beyond 1 year.
Early β blocker use was associated with reduced 30 day mortality in patients with acute myocardial infarction, and discontinuation of β blockers at one year was not associated with higher five year mortality. These findings question the utility of prolonged β blocker treatment after acute myocardial infarction in patients without heart failure or left ventricular dysfunction.Trial registration Clinical trials NCT00673036.
No takes yet. Share an insight, caveat, or question.
Puymirat et al. (2016) conducted a cohort in acute myocardial infarction without heart failure (n=2,679). β blockers vs. No β blockers was evaluated on 30 day mortality (HR 0.46, 95% CI 0.26 to 0.82, p=0.008). Early use of β blockers reduced 30 day mortality to 2.3% compared to 8.6% in non-users, with an adjusted.46.
Synapse has enriched 10 related papers. Consider them for comparative context: